Monica Bertagnolli
Monica Bertagnolli | |
|---|---|
Bertagnolli in 2023 | |
| 17th Director of the National Institutes of Health | |
| In office November 9, 2023 – January 17, 2025 | |
| President | Joe Biden |
| Deputy | Lawrence A. Tabak |
| Preceded by | Francis Collins |
| Succeeded by | Jay Bhattacharya |
| 16th Director of the National Cancer Institute | |
| In office October 3, 2022 – November 9, 2023 | |
| President | Joe Biden |
| Deputy | Douglas R. Lowy |
| Preceded by | Norman Sharpless |
| Succeeded by | Kimryn Rathmell |
| Personal details | |
| Born | 1959 (age 65–66) |
| Education | Princeton University (BS) University of Utah (MD) |
| Scientific career | |
| Fields | Surgical oncology Gastrointestinal cancer Adenomatous polyposis coli Colorectal cancer |
| Institutions | Dana–Farber Cancer Institute Harvard Medical School NewYork-Presbyterian Hospital |
Monica Bertagnolli (born 1959) is an American surgical oncologist and was the 17th director of the National Institutes of Health. She previously served as the 16th director of the National Cancer Institute (NCI). Prior to her governmental positions, she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School.
She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead the NCI. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas. She is the former President of the American Society of Clinical Oncology and was inducted into the National Academy of Medicine in 2021.